Difference between revisions of "Alternative Healthcare system reform"
Murat.akguc (talk | contribs) |
Murat.akguc (talk | contribs) |
||
| Line 12: | Line 12: | ||
form of increasing government demands for price cuts, as in Germany and the U.K., or | form of increasing government demands for price cuts, as in Germany and the U.K., or | ||
encouraged use of generics, as in Japan. | encouraged use of generics, as in Japan. | ||
In the U.S., in Europe the pharma industry is seeing a shift away from | |||
the model in which the physician is the major stakeholder. Payor organizations are taking on a more significant role, the distribution landscape is changing, and patients/consumers | |||
are taking on a larger role in healthcare decision making. | |||
===2015-2020=== | ===2015-2020=== | ||
===2020-2025=== | ===2020-2025=== | ||
Revision as of 17:40, 13 October 2009
Work under construction. In case you have any questions, additions or comments, please do not edit these pages, but you are more than welcome to contact us.
Scenario wherein the healthcare system is more integrated, shorter lines between pharma, medicine, insurance companies
Developments in time
2010-2015
At the beginning of 2009, the global economic environment was still in a major state of flux.In the United States, the actions of the Obama administration and Congress were committed to addressing healthcare issues as part of economic reform. The global economic slowdown sparked acceleration of reform in other countries as well, whether in the form of increasing government demands for price cuts, as in Germany and the U.K., or encouraged use of generics, as in Japan.
In the U.S., in Europe the pharma industry is seeing a shift away from the model in which the physician is the major stakeholder. Payor organizations are taking on a more significant role, the distribution landscape is changing, and patients/consumers are taking on a larger role in healthcare decision making.